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Abstract 
Purpose: To investigate the development of mammary tumours in female Sprague-dawley rats through 
a simple subcutaneous injection of human adenocarcinoma breast cells (MCF7) in combination with 
basement membrane matrix (BME).  
Methods: Nine Sprague-Dawley rats were divided into three groups. Group A received no injection, 
group B was injected with MCF7 cells at a cell density of 7.2 x 106/ml, and group C was co-injected with 
MCF7 and BME at 7.2 x 106/ml and 3.158 mg/ml, respectively. Tumour growth was observed over a 
duration of 70 days. Hematological analysis was performed using differential blood cell counts. 
Histological evaluation was carried out using standard LM techniques and H&E staining.  
Results: At day 35, RBC concentration across all groups was 8.10 x 106/mm3, whereas by day 70 the 
range decreased to (7.64 – 7.87) x 106/mm3. White blood cells (WBCs) were within normal range up to 
day 35, but monocytes and lymphocytes displayed an increase in concentration for group C. Mammary 
tissues from the thoracic region showed evidence of MCF7 cellular proliferation in both groups B and C.  
Conclusion: This study reveals that BME enhances tumour growth. Further studies are required to 
investigate optimization strategies for the development of mammary tumours in alternative recipient 
animal. 
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The study of cancer however is currently one of 
the most widely studied and dynamic fields in the 
forefront of animal research [1,2]. Subsequently 
the human breast adenocarcinoma adherent cell 
line (MCF7) and is currently is one of the most 
predominant cell lines used to study breast 
cancer cell biology in both, in vitro and in vivo 
experiments [3]. In addition this cell line is well 
characterised and therefore a suitable choice for 
breast cancer research involving tumour growth, 
hormone and other targeted drug related 
therapies. The most common in vivo technique 
within animal models involves the study of 
tumours [4].  
 
Many researchers demonstrated induction of 
mammary tumours in rats through the use of 
chemical carcinogens such as N-
methylnitrosurea, dimethylhydrazine and 7, 12-
dimethylbenz (a) anthracene [5-7]. Other 
chemical inducers of tumours include the 
administration of high doses of growth hormones, 
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oestrogens or aminofluorene compounds that 
stimulate the development of mammary tumours 
[8]. These chemical inducers are toxic and 
harmful to the animal upon administration and 
offers low tumour development or growth rates 
that may take up to 3-4 months before the 
appearance of an external tumour growth [9]. 
The development of rapid and efficient growth 
rate in xenograft techniques is achieved through 
the application of basement membrane extract 
(BME) [10-12]. This membrane extract is 
composed of collagen IV, heparin sulphate 
proteoglycan, laminin and various other growth 
factors that work synergistically to promote cell 
growth and tumour formation [13]. Numerous 
studies have been conducted to demonstrate the 
ability of BME to increase uniform 
tumourigenicity in xenograft applications. Most of 
these studies were performed on nude mice to 
induce mammary, pancreatic, prostate, lung and 
colorectal cancer tumours [10-14]. However 
these animals are immunocompromised and 
require specialized breeding, handling and 
application protocols [11,13].  
 
The current study aimed to demonstrate the 
tumour inducing ability of BME and MCF7 using 
Sprague-Dawley rats that have normal 







All the animal protocols conformed to the guiding 
principles of laboratory animal care (NIH 
Publication no. 85-93, revised 1985) [15] and 
were approved by the University of KwaZulu 
Natal (UKZN) Animal Ethics Committee 
(approval ref no. 085/14/Animal). All animal 
research was conducted at the Biomedical 
Resource Unit, UKZN under direct supervision of 
the Veterinary staff. The care and use of 
experimental animals in this study strictly 
complied with the approved UKZN animal 




Modified eagle medium (MEM), phosphate 
buffered saline (PBS), Trypsin, 100 x pen-strep 
Fungizone (PSF) and fetal calf serum (FCS) 
were supplied by Whitehead Scientific. Human 
breast (MCF7) adenocarcinoma cell lines were 
purchased from American Type Culture 
Collection (ATCC) and used in the experiments. 
This adhesion cell line was grown in MEM culture 




The vial containing a concentration of 3.158 
mg/ml of BME was removed from -80 oC storage, 
placed on ice and allowed to thaw 24 h prior to 
tumour induction. Cells that grew as monolayers 
were trypsinized at passage two and calculated 
at a total cell density of 7.2 x 106 per ml. 
Injections were prepared containing equal 
volumes of MCF7 cells and BME. A 22 gauge 
needle was used to carefully inject 1 ml of the 
preparations (MCF7 cells only or MCF7 + BME) 
subcutaneously into the right thoracic gland of 
the Sprague-Dawley female rats. 
 
Animals and conditions 
 
Four-week-old female, specific-pathogen free 
(SPF) Sprague Dawley rats were acquired from 
Biomedical Resource Unit, University of KwaZulu 
Natal. The nine rats were housed and 
acclimatised for 7 days before starting the 
experiments. During the acclimatisation and 
experimental periods, the rats were housed in 
polycarbonate cages (maximum of 3 rats per 
cage) in a room with controlled temperature (22.2 
± 1.7 °C), humidity (48.4 ± 6.0 %), and a 12-h 
light/dark cycle. The rats were fed rodent pellets 
and water ad libitum. The rats were divided into 
three groups (3 rats in each group). Group A was 
the untreated control animals that received no 
injection. The animals in group B received 
subcutaneous injection of human breast 
adenocarcinoma MCF7 cancer cells at a total cell 
density of 7.2 x 106 per ml, the animals in group 
C, received a co-injection of human breast 
adenocarcinoma MCF7 cancer cells at a total cell 




On day 35 of the study, each animal was placed 
in a warming chamber for a few minutes, 
followed by blood collection through the lateral 
tail vein using a 22 gauge needle. The blood (1 
ml) was collected in heparinized vacutainers. The 
animal feed was withheld to ensure a 12 h 
fasting before necropsy at the conclusion of the 
study. On day 70 of the study the animals were 
anesthetised by an overdose of halothane 
followed by immediate bleeding and 
exsanguination by cardiac puncture. Then blood 
was collected in heparinized vacutainers. White 
and red blood cell counts were analysed using a 




The injection site (mammary tissue) was carefully 
harvested, weighed and fixed in 10 % formalin 
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solution containing neutral phosphate-buffered 
saline, embedded in paraffin, stained with 
hematoxylin and eosin, followed by microscopic 
histological evaluations using light microscopy 
techniques. For light microscopy (LM) 
evaluations, the tissue samples were removed 
from the fixative and dehydrated using a 50 to 96 
% ethanol gradient with the ethanol being 
subsequently cleared from the tissue using 
xylene. The tissue was then embedded in 
paraffin wax using standard procedures. The wax 
embedded tissues were sliced into 3 µm sections 
using a microtome. The micro-sliced tissue 
sections were then collected on glass slides, 
dried and stained with hematoxylin and eosin 
(H&E) using standard protocols. The stained 
sections were examined using a light microscope 
(LM; Nikon 80i, Kanagawa, Japan) and images 
were digitally captured using NIS Elements D 
software and a camera (Nikon U2, Kanagawa, 
Japan). All tissue evaluations were performed 




Statistical analysis was performed using 
GraphPad Prism® Version 5 software. The 
statistical evaluation included a two-tailed 
Student’s t-test or analysis of variance (ANOVA). 
The level of statistical significance was set at p < 
0.05. Data was represented as the mean ± SD 




Animals during tumour induction study 
 
The animals’ behaviour, activity, mobility, 
alertness, grooming, feed and water 
consumption was monitored daily over the 70 
day study. The animals from all groups appeared 
healthy, active and alert in addition their food and 
water consumption observations remained 
constant throughout the 70 days. The baseline 
weight of the animals at the start of the study 
was between 150-160 g (Table 1). The weight of 
the animals at the end of the study was between 
217-227 g, which indicated a 70 % weight 
increase across all groups over the 70 day 
period. Weekly examinations were performed to 
evaluate the presence of a tumour mass. No 
solid or external growth was observed in group B 
and C. The tissue from the injection site was 
removed and processed for histopathology 
analysis. 
 
Hematological analysis of red and white 
blood cells 
 
At day 35 RBC concentrations across all groups 
were 8.10 x 106/mm3 (Figure 1 A), which is within 
the normal reference range of rat RBC (6.76-9.75 
x 106/mm3). There was no statistically significant 
change (p > 0.05) in the RBC values from day 35 
to 70 as the values obtained on day 70 were 
between (7.64 - 7.87) x 106/mm3 (Figure 1 B). 
The values obtained for the white blood cells 
(WBC) ranged between 3.5 and 4 x 103/mm3 at 
day 35 (Figure 1A). There was a decrease in 
concentration to (1.5 - 2.07) x 103/mm3 of WBC 
observed across all the groups at day 70; 
however, the decrease was not statistically 
significant when compared to day 35. P-values 
obtained were 0.1, 0.2 and 0.2 for group A, B 
and C respectively. Although there was a 
decrease in the WBC concentrations, group C, 
retained the highest WBC values at day 70 
(Figure 1B). 
 
Differential WBC counts were performed to 
establish if there were any changes in the 
individual WBC populations from day 35 to day 
70. The values obtained at day 35 were all within 
reference range for these cell populations (Figure 
2A). With the exception of the monocytes and 
lymphocytes, the results showed a statistically 
non-significant decrease (p > 0.05) in the other 
cell populations at day 70. The lymphocytes 
values increased from 65.23 to 77.67 % and 
67.73 to 81.20 % in groups B and C respectively 
(Figure 2B). Although there was an observable 
marked increase in these lymphocyte values, 
those increases were not statistically significant 
(p > 0.05). 
 
Table 1: Animal weight gain and tumour observations during the 70 day study. The data is represented as mean 
± SD (n=3) 
 
Variable Group A 
Untreated control 
Group B 
MCF7 cells  
Group C 
MCF7 cells+BME 
Initial body weight (g) 158 ± 5.57 161 ± 7.81 150.67 ± 6.66 
Final body weight (g) 225 ± 10.44 227 ± 5.51 217 ± 11.37 
Body weight increase (%) 70.40 ± 5.83 70.90 ± 5.21 69.44 ± 4.53 
Tissue removed from tumour 
site (g) 
0.57 ± 0.16 0.81 ± 0.09 1.05 ± 0.14 
Clinical observations N/A No signs of external 
tumour mass 
No signs of external tumour 
mass 
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Figure 1: White and red blood cell counts (A) Shows the levels at day 35. (B) Shows levels at day 70. The data is 
represented as mean ± SD. All values compared to their respective control (n = 3) 
 
 
Figure 2: Differential white blood cell counts (A) Shows the percentage of cell populations at day 35. (B) Shows 
the percentage of cell populations at day 35. The data is represented as mean ± SD. All values compared to their 




The tissue of interest for histopathology 
evaluations was obtained from the injection site, 
situated on the right thoracic glandular region. 
The photomicrographs from the untreated control 
group at 10 x magnification (Figure 3A), closely 
resembles that of normal white adipose tissue 
found in large closely packed masses between 
the lobules, with cells having regular morphology 
and peripherally located, darkly stained nuclei 
(Figure 3A). For comparative analysis of the 
tissue sections from group B (Figure 3B) and C 
(Figure 3C) at 10 x magnification, showed 
evidence of clusters of MCF7 cells growing within 
the mammary tissues of treated groups. Although 
both treated groups exhibited this growth pattern, 
the photomicrographs of the MCF7 cells + BME 
treated group showed larger clusters of MCF7 
cells inter-dispersed between the adipose cells 
when compared to the MCF7 treatment (Figure 
3E and Figure 3F). Quantitative analysis of the 
colony size was established through measuring 
the surface area occupied by the MCF7 cancer 
cells from multiple observations of the tissue 
sections. MCF7treated tissue sections displayed 
surface areas ranging from 504 to 788 µm2. 
MCF7+BME treated tissue sections displayed 





The objective of this study was to induce 
mammary tumours in Sprague-Dawley rats using 
MCF7 human cancer cells and xenograft 
techniques. The application of BME was used to 
increase MCF7 cell growth rate and promote 
formation of a tumour. An additional aim was to 
demonstrate the tumour-enhancing ability of 
BME in rat models. This method of tumour 
induction has been well studied and highly 
reported using immune compromised nude mice 
as the recipient animal model [16,17].  
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Figure 3: Histopathology of tissue sections from the tumour injection site using light microscopy. (A) Displays the 
tissue sections from group A at 10 x magnification. (B) Tissue sections from group B at 10 x magnification. (C) 
Tissue sections from group C at 10 x magnification. (D) Displays the localization of MCF7 cells within the adipose 
tissue of group B at 40 x magnification. (E) Displays larger clusters of MCF7 cells within the adipose tissue from 
group C at 40 x magnification (F) shows the growth of MCF7 cells from group C, in close proximity of blood 
supply at 100 x magnification.  (A=adipose cells, BV= blood vessel, F= fibrous interlobular tissue, N= Nucleus of 
adipose cells, CM= Cell membrane of adipose tissue, RBC= Red blood cell) 
 
In the current study, nine Sprague-Dawley rats 
were used. Throughout the 70 day study the 
animal’s maintained normal behaviour, mobility, 
alertness and feeding patterns. Groups B and C 
showed no evidence of external tumour growth 
within the 70 day study. In a similar previous 
study rat-derived mammary adenocarcinoma 
LA7 cells were used to induce tumours in 
Sprague Dawley rats [18]. This technique 
involved a subcutaneous injection of LA7 cells 
into the rat-mammary fat pad. The presence of 
an external tumour was observed at day 30 of 
the study. Barros et al, showed the presence of 
mammary tumours in Sprague-Dawley rats after 
91 days of induction with 7,12-
dimethylbenz(a)anthracene [19]. In another study 
tumour growth induced by the chemical 
carcinogen N-methyl-N-nitroso urea developed 
only after 140 - 175 days [7]. 
 
Generally blood vasculature is expected to 
increase as the tumour growth progresses.  A 
developing tumour requires increased blood 
supply to support the nutrient and oxygen 
demands of the rapidly growing cancer cells. 
This process is commonly termed angiogenesis 
which results in consequent increases in blood 
cell density. During tumour growth the red blood 
cell counts are expected to increase. 
Hematological analyses were performed across 
all groups at day 35 and 70 to monitor any 
changes in the red and white blood cell 
concentrations. In this study the red blood cell 
counts remained within the normal range as the 
presence of a tumour mass was not observed in 
animals from the tumour induced groups B and 
C. During tumourigenicity, white blood cells play 
key roles in identifying and destroying cancer 
cells. The white blood cells are differentiated into 
many cell types that have specific function within 
immune responses. Lymphocytes specifically 
have been reported to induce tumour cell 
destruction [20].  Abnormally low levels of 
lymphocytes have been implicated in the 
negative outcomes associated with cancer 
patients [21].  Studies show that increased levels 
of lymphocytes inhibit tumour growth and are 
also linked to reduced tumour recurrence [22]. 
The increased percentage of lymphocytes 
reported in this study could be in response to the 
introduction of the MCF7 cells in group B and C. 
The increase in the lymphocyte cell numbers has 
the potential to inhibit the growth of the injected 
MCF 7 cells and could therefore be implicated as 
one of the possible reasons for the restricted 
growth of these cells observed in the tumour 
induced groups.  
 
Breast tissue has unique morphology, composed 
of glandular units arranged in lobules, embedded 
in a mass of adipose tissue which is subdivided 
by collagenous and fibrous interlobular tissue 
[23]. In this study the presence of an external 
tumour was not observed in animals from group 
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B and C, however light microscopy evaluations 
confirmed that the MCF7 cancer cells localized 
and grew within the adipose cells that surrounds 
the lobules of the mammary tissue. The 
presence of internalized MCF7 cell colonies 
confirms that the xenograft technique was 
successful. The tissue morphology from groups 
B and C closely resembles the population density 
and orientation of MCF7 cells around the adipose 
tissue as reported in a study by Chang et al, 
using xenografts in nude mice [24]. Additional 
reports on breast cancer tissue morphology also 
support the findings of the current study [25]. 
 
Interestingly in the present study, the injected 
MCF7 cells confined their aggregation and 
growth very closely to either the cell membranes 
of the adipose cells or in very close proximity to 
blood vessels. This can be attributed to the 
MCF7 cells adhering to areas that have a rich 
nutrient supply that would enable their successful 
survival and allow them the ideal conditions to 
promote tumour growth. In addition the 
histopathology studies confirmed that the 
xenograft technique using MCF7 cells and BME 
was correctly performed. The surface area or 
colony size that the cancer cells occupied within 
the MCF7+BME treated (group C) were 
extensively larger compared to the MCF7 treated 
(group B).This finding is attributed to the tumour 
enhancing properties of BME, which promoted 
higher colony numbers and colony size. The 
larger clusters of cells observed in group B is 
attributed to the properties of BME in promoting 
and stimulating increased growth and adherence 
of higher cell numbers to the injection site.  The 
technique demonstrated the growth of MCF7 
cells in the thoracic region of the mammary 
gland, however the progression of external 
tumours in the presence of BME was 
unsuccessful.  
 
This study also demonstrated that the method of 
using cancer cells in combination with BME has 
the potential to induce tumours in rat models 
however the method may require further 
optimization. The induction of tumours using 
animal models that are not immunocompromised 
is a pivotal aspect of cancer research which has 
further downstream implications in clinical 
studies. The challenges in understanding cancer 
cell interactions and tumour physiology is 





The findings from this study show that MCF7 
cells and BME have the potential to induce 
mammary tumours in Sprague-Dawley rats. The 
growth of MCF7 cancer cells within the 
mammary tissues confirms the tumour enhancing 
properties of BME. Further optimization 
strategies need to be explored in order to 
establish a Sprague-Dawley breast cancer 
animal model that can be used to further develop 
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